Physician

Amarnath A Kathresal, M.D.

According to 2025 Medicare claims, Amarnath Kathresal, M.D. (NPI: 1033194402) practices nephrology in the Durham-Chapel Hill, NC market, with the plurality of this provider's patient population coming from Durham, NC. This provider's primary affiliated billing organization is DURHAM NEPHROLOGY ASSOCIATES PA (NPI: 1962583203; TIN: 561572881) and primary practice location at 27704-2702.

Kathresal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 375 traditional Medicare patients, billed 4,149 HCPCS/CPT codes, and received $148,593 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 1,528 prescription claims across 263 beneficiaries totaling $296,338 in drug costs, led by Jardiance (Empagliflozin). 2018 DME data shows 11 claims. Open Payments data shows 89 records totaling $163,182. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $301,125 to $148,593. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $431,794 and ending at $296,338. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	585	7,270	$301,125
2016	623	8,046	$276,342
2017	682	6,011	$306,855
2018	605	6,111	$289,767
2019	694	5,420	$321,393
2020	642	7,448	$330,639
2021	519	5,269	$258,157
2022	413	5,753	$165,183
2023	403	4,110	$138,023
2024	375	4,149	$148,593

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	257	2,568	$431,794
2016	270	2,576	$517,283
2017	263	2,516	$532,611
2018	239	2,143	$155,326
2019	256	1,772	$121,670
2020	311	1,963	$219,483
2021	312	1,860	$254,240
2022	268	1,511	$402,993
2023	268	1,602	$347,971
2024	263	1,528	$296,338

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$230
2018	N/R	11	$302
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	54	105	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	137	370	$57
90935	Hemodialysis procedure with physician evaluation	78	176	$53
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	61	96	$38
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	104	177	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	146	5,277	$99,874
Farxiga	Dapagliflozin Propanediol	97	4,131	$75,961
Velphoro	Sucroferric Oxyhydroxide	19	810	$51,821
Sevelamer Carbonate	Sevelamer Carbonate	23	1,208	$3,162
Torsemide	Torsemide	88	5,017	$2,568

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$989	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	37	$162,193	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amarnath A. Kathresal, M.D.?

Tedicare shows public-source Medicare data for Amarnath A. Kathresal, M.D. (NPI 1033194402), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amarnath A. Kathresal, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amarnath A. Kathresal, M.D.?

Amarnath A. Kathresal, M.D. is linked to DURHAM NEPHROLOGY ASSOCIATES PA (billing NPI 1962583203) in the available physician profile data.

Does Amarnath A. Kathresal, M.D. have Open Payments data?

Amarnath A. Kathresal, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.